TY - JOUR
T1 - The science of Durban, AIDS 2016
AU - Beyrer, Chris
AU - Shisana, Olive
AU - Baral, Stefan D.
AU - Milsana, Koleka
AU - Mayer, Kenneth H.
AU - Pozniak, Anton
AU - Walker, Bruce D.
AU - Mboup, Souleman
AU - Sohn, Annette H.
AU - Serwadda, David
AU - Rees, Helen
AU - Dvoriak, Sergii
AU - Warren, Mitchell
AU - Thiam, Safiatou
AU - El-Sadr, Wafaa M.
AU - Hospital, Xavier
AU - Ryan, Owen
AU - Thomson, Nicolas
AU - Bekker, Linda Gail
N1 - Funding Information:
The corresponding author’s time was supported, in part, by The Johns Hopkins University Center for AIDS Research (P30AI094189).
Funding Information:
1Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 2International AIDS Society, Geneva, Switzerland; 3Evidence Based Solutions, Cape Town, South Africa; 4Department of Medicine, University of KwaZulua Natal, Durban, South Africa; 5Department of Medicine, Harvard Medical School, Fenway Community Health Center, Boston, USA; 6Department of Medicine, Chelsea and Westminster Hospital, London, UK; 7Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; 8Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations, Dakar, Senegal; 9TREAT Asia, amfAR – The Foundation for AIDS Research, Bangkok, Thailand; 10Department of Epidemiology, Makerere University School of Public Health Kampala, Uganda; 11Wits RHI, University of the Witwatersrand, Johannesburg, South Africa; 12Ukrainian Institute on Public Health Policy, Kiev, Ukraine; 13AVAC, New York, NY, USA; 14Department of Health, National AIDS Council of Senegal, Dakar; 15Mailman School of Public Health, ICAP at Columbia University, New York, NY, USA; 16Department of Health, UNESCO Regional Office in Dakar, Dakar, Senegal; 17Desmond Tutu HIV Research Foundation, University of Cape Town, Cape Town, South Africa
Publisher Copyright:
© 2017 Beyrer C et al; licensee International AIDS Society.
PY - 2017
Y1 - 2017
N2 - Introduction: The science presented at the 21st International AIDS Conference in Durban, South Africa, in July 2016, addressed the state of the field across basic, clinical, prevention, law and policy and implementation science. Methods and Results: The AIDS response has seen remarkable achievements in scientific advances, in translation of those advances into prevention, treatment and care for affected individuals and communities, and in large scale implementation - reaching 18 million people with antiviral therapy by mid-year 2016. Yet incident HIV infections in adults remain stubbornly stable and are increasing in some regions and among adolescents and adults in some key populations, challenging current science, policy and programming. There have been important advances in both preventive vaccines and in cure research, but both areas require ongoing investment and innovation. Clinical research has flourished with new agents, regimens, delivery modes and diagnostics but has been challenged by aging and increasingly complex patient populations, long-term adherence challenges, co-infections and co-morbidities, and unresolved issues in TB management and epidemic control. It is an extraordinary period of innovation in prevention, yet the promise of new tools and combination approaches have yet to deliver epidemic HIV control. Conclusions: Proven interventions, most notably pre-exposure prophylaxis, PrEP, have been limited in rollout and impact. Treatment as prevention has the promise to improve clinical outcomes but remains uncertain as a prevention tool to reduce population-level HIV incidence. The improvement of legal, policy and human rights environments for those most at risk for HIV acquisition and most at risk for lack of access to essential services; sexual and gender minorities, sex workers of all genders, people who inject drugs, and prisoners and detainees remain among the greatest unmet needs in HIV/AIDS. Failure to do better for these individuals and communities could undermine the HIV response.
AB - Introduction: The science presented at the 21st International AIDS Conference in Durban, South Africa, in July 2016, addressed the state of the field across basic, clinical, prevention, law and policy and implementation science. Methods and Results: The AIDS response has seen remarkable achievements in scientific advances, in translation of those advances into prevention, treatment and care for affected individuals and communities, and in large scale implementation - reaching 18 million people with antiviral therapy by mid-year 2016. Yet incident HIV infections in adults remain stubbornly stable and are increasing in some regions and among adolescents and adults in some key populations, challenging current science, policy and programming. There have been important advances in both preventive vaccines and in cure research, but both areas require ongoing investment and innovation. Clinical research has flourished with new agents, regimens, delivery modes and diagnostics but has been challenged by aging and increasingly complex patient populations, long-term adherence challenges, co-infections and co-morbidities, and unresolved issues in TB management and epidemic control. It is an extraordinary period of innovation in prevention, yet the promise of new tools and combination approaches have yet to deliver epidemic HIV control. Conclusions: Proven interventions, most notably pre-exposure prophylaxis, PrEP, have been limited in rollout and impact. Treatment as prevention has the promise to improve clinical outcomes but remains uncertain as a prevention tool to reduce population-level HIV incidence. The improvement of legal, policy and human rights environments for those most at risk for HIV acquisition and most at risk for lack of access to essential services; sexual and gender minorities, sex workers of all genders, people who inject drugs, and prisoners and detainees remain among the greatest unmet needs in HIV/AIDS. Failure to do better for these individuals and communities could undermine the HIV response.
KW - HIV
KW - human rights
KW - implementation science
KW - prevention
KW - treatment
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85037591457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037591457&partnerID=8YFLogxK
U2 - 10.7448/IAS.20.1.21781
DO - 10.7448/IAS.20.1.21781
M3 - Review article
C2 - 28692209
AN - SCOPUS:85037591457
SN - 1758-2652
VL - 20
JO - Journal of the International AIDS Society
JF - Journal of the International AIDS Society
IS - 1
M1 - 21781
ER -